News Search Results
Oct 09, 2025, 06:23 ET GlyTR Therapeutics announces landmark study in Cell on their 'Velcro-like' Pan-Cancer Immunotherapy Platform
https://doi.org/10.1016/j.cell.2025.09.001 About GlyTR Therapeutics GlyTR Therapeutics is a biotechnology company developing first-in-class immunotherapies that unlock tumor-associated carbohydrate antigens (TACAs) as pan-cancer targets. Backed by grants
More news about: GlyTR Therapeutics
Oct 09, 2025, 06:02 ET Lupin Unveils Strategic Partnership Program to Expand Reach of its Long-Acting Injectable Platform
products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Limited
Oct 09, 2025, 05:58 ET Lupin Unveils Strategic Partnership Program to Expand Reach of its Long-Acting Injectable Platform
products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Limited
Oct 09, 2025, 05:11 ET Chance Pharma Announces Commercialization Agreement with Huadong Medicine for Innovative Respiratory Drug CXG87
China, Oct. 9, 2025 /PRNewswire/ -- Chance Pharmaceuticals ("Chance" or "Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inhalation therapies, today announced that it has reached an exclusive commercialization
More news about: Chance Pharmaceuticals
Oct 09, 2025, 03:00 ET ARTHEx Biotech to Participate in Upcoming Investor and Industry Events
Valencia, Spain, Oct. 9, 2025 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing targeted RNA medicines for rare genetic neuromuscular disorders, announced today its participation in the following
More news about: ARTHEx Biotech
Oct 08, 2025, 23:41 ET Driving Veterinary Healthcare Forward: Anbio Showcases Diagnostic Portfolio at WSAVA 2025
contributes to improving healthcare outcomes in diverse settings worldwide. About Anbio BiotechnologyAnbio Biotechnology is a globally oriented in vitro diagnostics (IVD) company providing a broad range of solutions, including immunofluorescence, dry
More news about: Anbio Biotechnology
Oct 08, 2025, 16:30 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc. and Certain Officers - UNCY
for information about joining the class action] Unicycive is a clinical-stage biotechnology company that identifies, develops, and commercializes therapies to address unmet medical needs in the U.S. The Company is developing, among other
More news about: Pomerantz LLP
Oct 08, 2025, 16:30 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR
here for information about joining the class action] Jasper, a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria ("CSU"), Chronic Inducible
More news about: Pomerantz LLP
Oct 08, 2025, 16:15 ET WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has entered into definitive agreements
More news about: WallachBeth Capital LLC
Oct 08, 2025, 12:35 ET Rubin Rudman Adds Laura Kirshenbaum as a Partner in Labor & Employment Group
Rubin Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; regulated industries, public entities and municipalities; insurance companies and their insureds; educational
More news about: Rubin Rudman
Oct 08, 2025, 11:00 ET TCI Biotech Releases 2024 ESG Report, Showcasing Brand Transformation, Global Sustainability Commitments, and Award-Winning Impact
SALT LAKE CITY, Oct. 8, 2025 /PRNewswire/ -- TCI Biotech, a global biotechnology leader in health and wellness, today announced the release of its 2024 Environmental, Social, and Governance (ESG) Report, marking a milestone year
More news about: TCI; TCI Biotech
Oct 08, 2025, 10:30 ET Industrial Gases Market Size to Lead USD 365.65 Billion at 11.95% CAGR by 2035 | Vantage Market Research
market research reports and actionable intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions, anticipate trends, and capitalize
More news about: Vantage Market Research
Oct 08, 2025, 10:20 ET C-Ray Therapeutics (Shanghai) Co., Ltd. Presents Breakthrough Clinical Data of Novel Targeted Alpha Therapy 225Ac-PSMA-CY313 at EANM 2025
About C-Ray Therapeutics (Shanghai) Co., Ltd. C-Ray Therapeutics (Shanghai) is a biotechnology company focused on the discovery and development of innovative targeted radiopharmaceuticals. Based in Shanghai, the company is advancing its pipeline
More news about: C Ray Therapeutics
Oct 08, 2025, 10:10 ET Dental Implants Market to Reach USD 15.14 Billion by 2035, Growing At a 9.95% CAGR | Vantage Market Research
Browse More Related Reports: Biotechnology Market is valued at USD 1.77 Trillion in 2024 and is projected to reach a value of USD 7.417 Trillion by 2035 at a CAGR (Compound Annual Growth
More news about: Vantage Market Research
Oct 08, 2025, 09:55 ET Radiance Technologies and Louisiana Tech Win DARPA Contract to Pioneer Microsystem-Induced Catalysis
Louisiana," said Radiance CEO Bill Bailey. "We're excited to help advance national capabilities while strengthening the region's role in the future of biotechnology." About Radiance Technologies: Radiance Technologies is
More news about: Radiance Technologies
Oct 08, 2025, 09:31 ET India's No: 1 Ranked Institute, IIT Madras & Danish University Study reveals Genetic 'Switches' that can transform Disease Research
Department of Biotechnology, IIT Madras, in collaboration with Dr. Shannara Taylor Parkins and Dr. Suresh Sudarsan from the Technical University of Denmark. Elaborating on the importance of this research, Prof. Himanshu Sinha, Department of Biotechnology, IIT Madras,
More news about: IIT Madras
Oct 08, 2025, 09:26 ET India's No: 1 Ranked Institute, IIT Madras & Danish University Study reveals Genetic 'Switches' that can transform Disease Research
Department of Biotechnology, IIT Madras, in collaboration with Dr. Shannara Taylor Parkins and Dr. Suresh Sudarsan from the Technical University of Denmark. Elaborating on the importance of this research, Prof. Himanshu Sinha, Department of Biotechnology, IIT Madras,
More news about: IIT Madras
Oct 08, 2025, 08:30 ET Best Practices to Ensure a Smooth CRO Handoff and Data Continuity, Upcoming Webinar Hosted by Xtalks
clinical operations, data management, biostatistics and programming, safety and pharmacovigilance, and medical writing for the biopharmaceutical and biotechnology industries. As a multi-therapeutic functional service provider (FSP) organization, Catalyst Flex delivers the right people, process and technology
More news about: Xtalks
Oct 08, 2025, 08:30 ET ICH GCP E6(R3): Navigating the New Era of Good Clinical Practice, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 08, 2025, 08:30 ET Ensure Product Efficacy and Patient Safety with Benzalkonium Chloride, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 08, 2025, 08:30 ET ImmunoVec Launches from Stealth with up to $40.7 Million ARPA-H EMBODY Award to Advance In Vivo Cell Engineering Platform for Autoimmune Diseases
LOS ANGELES, Oct. 8, 2025 /PRNewswire/ -- ImmunoVec, a biotechnology company pioneering a novel approach to in vivo cell engineering, today announced its launch from stealth with an up to $40.7 million award from
More news about: ImmunoVec
Oct 08, 2025, 08:05 ET Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS
Calif., Oct. 8, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the first patient has been enrolled in the dose expansion phase of the ongoing
More news about: Rigel Pharmaceuticals, Inc.
Oct 08, 2025, 08:02 ET Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform
compliance. Hoth's AI initiative complements its broader strategy of digital transformation and innovation in biotechnology, enabling partnerships with advanced AI-driven platforms and life-science data companies to optimize development timelines, reduce costs, and improve
More news about: Hoth Therapeutics, Inc.
Oct 08, 2025, 08:01 ET TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company
(NASDAQ: RNAZ) ("TransCode or the "Company") announced today that it entered into a definitive agreement to acquire Polynoma LLC, a privately-held biotechnology immuno-oncology company. Polynoma is developing a late-stage candidate, seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant
More news about: TransCode Therapeutics, Inc.
Oct 08, 2025, 08:00 ET CREATE Medicines Strengthens Executive Team with Appointment of Veteran Biopharma Leader Allan L. Shaw as CFO and CBO
CAMBRIDGE, Mass., Oct. 8, 2025 /PRNewswire/ -- CREATE Medicines, a clinical-stage biotechnology company pioneering RNA-based in vivo multi-immune programming, today announced the appointment of Allan L. Shaw as Chief Financial Officer (CFO)
More news about: CREATE Medicines, Inc.